^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Renal Cell Carcinoma
    Drug:sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Excerpt:
    Sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    SUTENT is a kinase inhibitor indicated for:...the treatment of advanced renal cell carcinoma (RCC)….the adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Published date:
    09/28/2021
    Excerpt:
    Medical treatment for advanced/metastatic papillary RCC...Alternative options include sunitinib [II, B], pembrolizumab [III, B] without additional molecular testing and savolitinib (where available) in MET-driven tumours [III, C].
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Sunitinib is listed as a category 2A preferred option for treatment-naïve patients with stage IV non-clear cell RCC.